COVID-19 Saliva-based Screening Market Segmented By Saliva Collection Kits, Saliva Nucleic Acid Purification Kits, Saliva-based Detection Kits Product with Direct Sample to PCR, RT-qPCR, Lateral Flow Assays Technology
Industry: Healthcare
Published Date: December-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 328
Report ID: PMRREP32712
Worldwide revenue from the COVID-19 saliva-based screening market stands at US$ 2.1 Bn in 2022, with the global market estimated to decline at a CAGR of -1.5% to reach US$ 1.6 Bn by the end of 2033.
| Attributes | Key Insights |
|---|---|
|
COVID-19 Saliva-based Screening Market Size (2022) |
US$ 2.1 Bn |
|
Projected Market Value (2033) |
US$ 1.6 Bn |
|
Global Market Growth Rate (2023-2033) |
-1.5% CAGR |
|
Market Share of Top 5 Countries |
60.5% |
As assessed by Persistence Market Research, saliva-based detection kits contributed the largest share of 82.8% in the product category in 2022. The COVID-19 saliva-based screening market holds approximately 1% of the global health screening market valued at US$ 241.1 Bn in 2022.
The global market for COVID-19 saliva-based screening market recorded a historic CAGR of 9.9% in the last 2 years from 2020 to 2022.
The overall market for COVID-19 saliva-based screening products is likely to decline over time due to a growing focus on vaccination throughout regions, support from developing countries that can offer vaccinations to non-developed regions, and the population developing vaccination.
The disease has had a very high incidence rate ever since the COVID-19 pandemic in 2019. It had an impact on almost all nations in the world. The number of cases worldwide increased exponentially after COVID-19 was identified.
Developing nations like India saw similar effects as industrialised ones like the United States and Europe experienced. The virus's high level of inter-person transmission was a crucial factor in its fast expansion. Worldwide demand for COVID-19 diagnostics increased as a result of this, demanding companies to enter into this space with increased R&D and subsequently COVID-19 diagnostic kits and vaccines development.
Demand for COVID-19 testing has increased as a result of the COVID-19 pandemic. In addition, there have been instances of the second wave in a few countries over the past two quarters, and the second and third waves are expected to spread to additional nations and the market is likely to show steady growth over the coming years.
“Improvement of COVID-19 Testing and International Funding”
Saliva-based techniques can help testing programmes in low- and middle-income nations become more affordable, scalable, and sustainable. Saliva is more sensitive than anterior nasal and mid-turbinate swabs in early infection detection, and it is equally as effective at detecting SARS-CoV-2.
This observation has held true in the wake of the emergence and global dissemination of the Omicron strain of SARS-CoV-2. Saliva testing aids lower- and middle-income nations in overcoming two major issues: a lack of resources and overworked medical workers.
Comparatively speaking, saliva-based testing methods are less expensive. Saliva samples do not need pricey, specialised collection tubes because they are stable without preservatives and cold-chain management. Additionally, saliva-based testing does not call for highly skilled medical personnel, specific swab supplies, or personal safety gear.
When compared to nasopharyngeal swabs, a meta-analysis calculated that saliva collection saves up to US$ 633,000 for every 100,000 patients sampled. Additionally, patients can self-collect saliva at clinics and testing facilities, lessening their discomfort.
Additionally, because there are fewer healthcare employees per capita in lower- and middle-income nations than in high-income ones, the strategy lowers the danger of occupational exposure to infection for healthcare professionals.
“Nasal Swab- Competition for Market Players”
Other specimens, like blood and nasopharyngeal swabs for detection, are what drive the industry today. Due to the ease with which saliva may be used for both self-detection and clinical purposes, its use is increasing substantially.
Despite this, a lot of new businesses are releasing testing kits that use nasal swabs, which is limiting the market growth.
One of the biggest constraints as human health behaviours is the completion of global vaccination. COVID-19 testing has been reduced due to immunisation consolidation.
Why is the U.S. COVID-19 Saliva-based Screening Market Booming?
“Government Funding Programs for COVID-19”
The U.S. accounted for a 31.7% share of the global market in 2022, and a similar trend is expected over the forecast period.
The World Health Organization (WHO) reported over 96.8 million confirmed cases of COVID-19 in the United States as of November 11, 2022. In terms of revenue and profitability, United States currently leads the COVID-19 saliva screening market and will continue to do so during the forecast period. Of the 50 states that have been affected, California, Texas, and Florida have reported the most instances overall.
This is because of the presence of key competitors in the country, high healthcare costs, and growing use of novel technologies in hospitals.
Why is China Emerging as a Prominent Market for COVID-19 Saliva-based Screening Suppliers?
“Rising Requirement of COVID-19 Saliva-based Testing”
China held the largest market share of 89.1% of the East Asia COVID-19 saliva-based screening market in 2022, with a market value of US$ 151.5 Mn.
According to the Journal of the Chinese Medical Association in one study, 205 oropharyngeal and 490 nasopharyngeal swabs from 213 hospitalised SARS-CoV-2 patients were analysed at various stages of the disease's progression. Regardless of whether the patients had mild or severe disease, they discovered that nasopharyngeal swabs had generally higher positive rates (53.6%-73.3%) than oropharyngeal (throat) swabs (11.1%-61.3%).
Despite immunisation campaigns, most people in China have not yet received the vaccine, and the vaccine is ineffective against mutant versions. As a result, the first appearance of a new variant in China opens up a variety of options for established local players.
Will India be a Lucrative Market for COVID-19 Saliva-Based Screening?
“High Prevalence of COVID-19 and Increasing Saliva-Based Screening”
In 2022, India held around 75.7% share of the South Asian market.
To meet patient demand for diagnosis and treatment in the event of such a pandemic, India faces enormous challenges. The second wave of COVID-19 patients overloaded diagnostic facilities, leading to increased cross-infection and COVID-19 spread. With the aid of saliva-based detection kits, this can be reduced.
Self-detection kits are becoming more popular as a way for people to obtain test results with less danger of cross-infection. Future market developments in India may benefit from this.
Which Technology is driving the Global Market Growth?
“Rising Incidence of COVID-19”
The technology sector is anticipated to have the highest demand for RT-qPCR testing, and it is anticipated to continue to account for a significant portion of revenue, almost 48.9%, as it did in 2022.
An effective screening method for cruise ships, airlines, sporting venues, and colleges is COVID-19 saliva screening antigen/antibodies testing, which enables quick identification of those who are currently contagious. The COVID-19 saliva-screening test for antigens and antibodies has the potential to significantly reduce the risks of the pandemic.
Moreover, a larger population over the age of 65 is likely to be at risk of developing the condition, as evidenced by the rising number of the mentioned age group. As a result, the demand for COVID-19 saliva-based screening is anticipated to increase as the population ages and becomes more vulnerable to viral infections.
Which COVID-19 Saliva-based Detection Product is Driving Market Growth?
“Home-Based Testing for SARS-COVID-19 Infection will Drive Market”
In 2022, saliva based detection kits dominated the product category with 82.8% of the COVID-19 saliva-based detection market. Over the decade, saliva-based detection as a specimen is predicted to fuel market expansion due to rising awareness of home-based testing for SARS-COVID-19 infection.
Over the projected period, PCR-based kits will dominate the market. Due to the growing use of COVID-19 saliva-based detection kits, there is a high demand for these products.
PCR-based kits for the identification of the SARS-CoV-2 coronavirus provide high sensitivity and specificity. Due to widespread knowledge of COVID-19 detection, self- testing is also rising.
Why Market Share for COVID-19 Diagnostics is high in the Application Segment?
“Growing Awareness of COVID-19 Detection”
In 2022, the COVID-19 diagnostics category held the highest share with over 62.7%.
After 2-3 months from release from lockdowns, more COVID-19 cases were seen as a result of people failing to maintain social distancing in public settings. As a result, many nations made the diagnosis of COVID-19 mandatory.
In order to interrupt the cycle, people also learned more about COVID-19 treatment methods and testing. Even those with weak flu or cough symptoms underwent detection tests.
As a result, there is a higher need for COVID-19 testing. To meet demand, RT-PCR is the most effective way to use saliva to quickly and accurately detect COVID-19 infection.
Why are Diagnostic Laboratories in Such High Demand?
“Growing Awareness of COVID-19 Detection”
In 2022, diagnostic laboratories held 26.9% share of the global market, which is the highest among the end users segment.
In order to detect pathogen-specific nucleic acids in samples, qPCR uses sequence-specific primers and probes to monitor the amplification of the nucleic acid molecules during PCR. The SARS-CoV-2 viral genome's relative stability facilitates the construction of PCR primers and probes for laboratory identification.
Due to the rising COVID-19 prevalence and increased virus mutation, which has boosted the demand for quicker and more accurate detection, diagnostic laboratories will present lucrative market growth opportunities. Laboratories have been crucial in verifying the diagnosis of COVID-19 and identifying affected people, but this segment has also faced significant challenges in the fight against this rapidly spreading and fatal disease.
Several leading players are focusing on advancements in in-vitro diagnostic procedures with rapid testing and expanding their product portfolios through the commercialization of products and product launches to increase their customer base and expand their sales footprint across the globe.
For instance,
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the COVID-19 saliva-based screening market, which are available in the full report.
| Attribute | Details |
|---|---|
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2020-2022 |
|
Market Analysis |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Product:
Technology:
Application:
End User:
Region:
To know more about delivery timeline for this report Contact Sales
The global market for COVID-19 saliva-based screening is valued at around US$ 2.1 Bn in 2022.
By 2033, the market for COVID-19 saliva-based screening is anticipated to decline at a CAGR of -1.5% and reach US$ 1.6 Bn.
Demand for COVID-19 saliva-based screening increased at 9.9% CAGR from 2020 to 2022.
With a combined market share of 60.5% in 2022, the U.S., Russia, India, China, and U.K. accounted for the majority of demand for the COVID-19 saliva based screening market.
The U.S. accounted for a 31.7% share of the global market in 2022.
Thermo Fisher Scientific, Qiagen, and Hologic are the top three manufacturers of the COVID-19 Saliva-based Screening kits.
China held a share of 89.1% in the East Asian market in 2022.
The Russia COVID-19 saliva-based screening market is valued at US$ 157.4 Mn in 2022.
Indian market in estimated to grow with the growth rate of -3.6% over the forecast period.
European market is expected to decline at a CAGR of -1.3% during the forecast period.
